DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Transderm Scop (Scopolamine Transdermal) - Summary

 
 



TRANSDERM SCOP SUMMARY

The Transderm Scop (transdermal scopolamine) system is a circular flat patch designed for continuous release of scopolamine following application to an area of intact skin on the head, behind the ear. Each system contains 1.5 mg of scopolamine base.

Transderm Scop is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area.


See all Transderm Scop indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Transderm Scop (Scopolamine Transdermal)

Nausea and Vomiting
Source: MedicineNet Angina Specialty [2014.07.09]
Title: Nausea and Vomiting
Category: Diseases and Conditions
Created: 1/31/2005 8:21:00 AM
Last Editorial Review: 7/9/2014 12:00:00 AM

more news >>

Published Studies Related to Transderm Scop (Scopolamine Transdermal)

Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. [2013]
information can predict treatment response to scopolamine in MDD... CONCLUSION: These results implicate cholinergic and visual processing dysfunction

Randomized, double-blind comparison of oral aprepitant alone compared with aprepitant and transdermal scopolamine for prevention of postoperative nausea and vomiting. [2012]
and vomiting (PONV) treated with oral aprepitant with or without scopolamine... CONCLUSIONS: This trial evaluating the effectiveness of aprepitant alone and in

A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. [2012]
reactions... CONCLUSIONS: Higher efficacy, a lower rate of adverse reactions, and convenience

Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. [2011.12]
RATIONALE: Enhancement of histaminergic neurotransmission or histaminergic plus cholinergic neurotransmission may represent novel strategies for improving cognition in Alzheimer's disease. OBJECTIVE: To evaluate the effects of a novel histamine H3 receptor inverse agonist (MK-3134), an acetylcholinesterase inhibitor (donepezil), and their combination in attenuating the cognitive impairment associated with scopolamine... CONCLUSIONS: Exploratory analyses provide evidence for cognitive improvement through inverse agonism of the H3 histamine receptor and for cooperation between human cholinergic and histaminergic neurotransmitter systems. (ClinicalTrials.gov trial registration number: NCT01181310).

Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. [2011.06]
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT: * Several lines of evidence suggest a possible role of 5-HT(6) receptor antagonists in dementia or cognitive dysfunction of schizophrenia. SB-742457 is a potent 5-HT(6) antagonist and has shown efficacy in different animal models of cognitive impairment. It is currently in development as a cognitive enhancer. Risperidone, commonly used to control agitation and psychotic features in both schizophrenia and Alzheimer's disease, is a D(2)/5-HT(2A ) antagonist with low affinity for 5-HT(6) receptors and limited effects on cognitive parameters. WHAT THIS STUDY ADDS: * As the combination of risperidone and SB-742457 may constitute a reasonable combination in cognitively impaired patients, pharmacodynamic interaction effects were investigated in this study. The only significant drug-drug interaction was a small increase of electroencephalogram (EEG) alpha and beta bands, which might suggest mild arousing activity of SB-742457 on the central nervous system-depressant effects of risperidone. The clinical relevance of these findings in patients remains to be established. Additionally, this study provided an extensive multidimensional pharmacodynamic profile of risperidone in healthy volunteers, showing that this antipsychotic suppresses motor performance (eye-hand coordination, finger tapping and postural stability), alertness, memory and neurophysiological functions (saccadic eye movements and EEG power spectrum). AIM: Several lines of evidence suggest a possible role of 5-HT(6 ) receptor antagonists in cognitive dysfunction of schizophrenia. Atypical antipsychotics, such as risperidone, are currently used in these disorders. Therefore, the pharmacological interactions between the 5-HT(6) antagonist SB-742457 and risperidone were investigated in the light of possible co-medication... CONCLUSION: The pharmacokinetic interactions between SB-742457 and risperidone detected in this study were not clinically relevant. The increase in EEG alpha and beta power is incompatible with enhanced risperidone activity, but could point to mild arousing effects of the combination. Most pharmacodynamic changes of risperidone are consistent with previously reported data. The potential cognitive effects of SB-742457 remain to be established. (c) 2011 Centre for Human Drug Research. British Journal of Clinical Pharmacology (c) 2011 The British Pharmacological Society.

more studies >>

Clinical Trials Related to Transderm Scop (Scopolamine Transdermal)

Scopolamine to Treat Depression
This study will examine the antidepressant effects of scopolamine in patients with major depressive disorder or bipolar disorder. Scopolamine is commonly used to treat motion sickness and diarrhea, and is sometimes given before anesthesia or during eye examinations. In preliminary studies, scopolamine has shown strong antidepressant effects when given as an intravenous (through a vein) infusion. This study will examine its effectiveness when given through a skin patch and in pill form.

People between 18 and 50 years of age who have major depressive disorder or bipolar disorder may be eligible for this study. Candidates are screened with a physical exam, electrocardiogram (EKG), eye exam, blood and urine tests, psychiatric and clinical interviews and neuropsychological testing.

Participants wear skin patches behind the ear and take pills according to a prescribed regimen over an 8-week period. Half of the time the medications contain scopolamine and half of the time they contain an "active" placebo called glycopyrrolate, a drug that produces side effects similar to those that may be experienced with scopolamine, but that does not go into the brain.

Participants come to the NIH Clinical Center every 4 to 5 days while taking the medication and then for two follow-up visits over the next 2 weeks for a physical exam and evaluations with clinical rating scales. In addition, participants are asked to undergo two sessions of cognitive testing and to have two positron emission tomography (PET) studies. Those who have the PET scans also have a magnetic resonance imaging (MRI) scan. Participants can choose to participate in the rest of the study without doing the PET scan.

PET is a diagnostic imaging tool that uses a radioactive chemical "tracer" to show cellular activity in specific tissues of the body. For this procedure, a catheter (thin plastic tube) is placed into an arm vein for injecting the tracer, and a second catheter is inserted into an artery in the wrist to obtain arterial blood samples during the scan. The patient lies on the scanner bed, wearing a special mask that is placed over the head to limit movement during the scan. MRI uses a magnetic field and radio waves to produce pictures of the brain. For this test, the subject lies on a table that is moved into the scanner (a metal cylinder), wearing earplugs to muffle the noise of the machine during the scan.

Cholinergic Modulation of Condition and Emotion in Mood Disorders: Functional Neuroimaging Studies [Recruiting]

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC) [Recruiting]
A study to evaluate safety and efficacy of topical sirolimus to treat plantar keratoderma in adults with PC. Subjects may receive either placebo or treatment with at least 1 foot receiving topical sirolimus at some time. For certain phases of the study treatment assignment to the right and left foot will be randomized in a double blind fashion. Blood levels will test systemic absorption of sirolimus. Other safety and efficacy measures will be taken through the 39-week study duration.

Topical Sirolimus for Plantar Keratoderma in Adults With Pachyonychia Congenita (PC) [Recruiting]
The primary objective of this study is to assess the safety of topical sirolimus (TD201) 1% for plantar keratoderma for the treatment of pachyonychia congenita. This study would also like to assess the potential of sirolimus (TD201) to improve the clinical severity of plantar keratoderma, including pain.

more trials >>

Reports of Suspected Transderm Scop (Scopolamine Transdermal) Side Effects

Nausea (18)OFF Label USE (16)Vomiting (14)Dizziness (13)Mydriasis (11)Vision Blurred (8)Confusional State (6)Therapeutic Response Unexpected (6)Inappropriate Schedule of Drug Administration (6)Withdrawal Syndrome (6)more >>


Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014